The S&P 500 Index ($SPX ) (SPY ) Tuesday closed down -0.28%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down -0.08%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -0.36%. Stock indexes...
/PRNewswire/ -- Invitae (NYSE: NVTA) and Praxis Precision Medicines, Inc. (NASDAQ: PRAX), today announced that real-world clinical insights from Invitae's...
PRAX-944 Phase 2b Essential1 Study topline results expected in 4Q22; primary endpoint updated to efficacy PRAX-562 Phase 1 study completed, confirming...
BOSTON, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic...
The current global macro-economic environment has not been kind to stock market investors. Record-high inflation levels and rising interest rates have resulted in muted returns, making investment decisions...
Praxis (PRAX) posts negative data from the phase II/III Aria study that evaluated PRAX-114 for monotherapy treatment of major depressive disorder. Shares fall.
Aria Study did not achieve statistical significance on the primary endpoint Strategic realignment to focus resources on Movement Disorders and Epilepsy...
BOSTON, May 23, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic...
BOSTON, May 11, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic...
PRAX-944 demonstrated clinically meaningful functional improvement in essential tremor patients in Part B of Phase 2a study Mean improvement at Day 42 was...